| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Concise Reviews |
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
Key Words. Dendritic cells • Tumor vaccines • Peptide vaccines • Vaccine adjuvants
Dr. Jose I. Mayordomo, Servicio de Oncologia Medica, Hospital Clinico Universitario, Avenida Gomez Laguna s/n, 50009, Zaragoza, Spain.
Dendritic cells (DCs) are considered the most effective antigen-presenting cells (APCs) for primary immune responses. Since presentation of antigens to the immune system by appropriate professional APCs is critical to elicit a strong immune reaction and DCs seem to be quantitatively and functionally defective in the tumor host, DCs hold great promise to improve cancer vaccines. Even though they are found in lymphoid organs, skin and mucosa, the difficulty of generating large numbers of DCs has been a major limitation for their use in vaccine studies. A simple method for obtaining DCs from mouse bone marrow cells cultured in the presence of GM-CSF + interleukin 4 is now available. In four different tumor models, mice injected with DCs grown in GM-CSF plus interleukin 4 and prepulsed with a cytotoxic T lymphocyte-recognized tumor peptide epitope developed a specific cytotoxic T lymphocyte response and were protected against a subsequent tumor challenge with tumor cells expressing the relevant tumor antigen. Moreover, treatment of day 5-14 tumors with peptide-pulsed DCs resulted in sustained tumor regression in five different tumor models. These results suggest that presentation of tumor antigens to the immune system by professional APCs is a promising method to circumvent tumor-mediated immunosuppression and is the basis for ongoing clinical trials of cancer immunotherapy with tumor peptide-pulsed DCs.
This article has been cited by other articles:
|
|
 |
|
  S Nagaraj, C Ziske, J Strehl, D Messmer, T Sauerbruch, and I. Schmidt-Wolf Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo Int. Immunol., August 1, 2006; 18(8): 1279 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Breckpot, J. Corthals, A. Bonehill, A. Michiels, S. Tuyaerts, C. Aerts, C. Heirman, and K. Thielemans Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response J. Leukoc. Biol., October 1, 2005; 78(4): 898 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terme, E. Tomasello, K. Maruyama, F. Crepineau, N. Chaput, C. Flament, J.-P. Marolleau, E. Angevin, E. F. Wagner, B. Salomon, et al. IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules J. Immunol., May 15, 2004; 172(10): 5957 - 5966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schmidt, C. Ziske, A. Marten, S. Endres, K. Tiemann, V. Schmitz, M. Gorschluter, C. Schneider, T. Sauerbruch, and I. G. H. Schmidt-Wolf Intratumoral Immunization with Tumor RNA-Pulsed Dendritic Cells Confers Antitumor Immunity in a C57BL/6 Pancreatic Murine Tumor Model Cancer Res., December 15, 2003; 63(24): 8962 - 8967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Devaraj, M. L. Gillison, and T.-C. Wu DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA Crit. Rev. Oral. Biol. Med., September 1, 2003; 14(5): 345 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tschoep, T. C. Manning, H. Harlin, C. George, M. Johnson, and T. F. Gajewski Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines J. Leukoc. Biol., July 1, 2003; 74(1): 69 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ribas, L. H. Butterfield, J. A. Glaspy, and J. S. Economou Current Developments in Cancer Vaccines and Cellular Immunotherapy J. Clin. Oncol., June 15, 2003; 21(12): 2415 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Steptoe, J. M. Ritchie, and L. C. Harrison Increased Generation of Dendritic Cells from Myeloid Progenitors in Autoimmune-Prone Nonobese Diabetic Mice J. Immunol., May 15, 2002; 168(10): 5032 - 5041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Spisek, P. Chevallier, N. Morineau, N. Milpied, H. Avet-Loiseau, J.-L. Harousseau, K. Meflah, and M. Gregoire Induction of Leukemia-specific Cytotoxic Response by Cross-Presentation of Late-Apoptotic Leukemic Blasts by Autologous Dendritic Cells of Nonleukemic Origin Cancer Res., May 1, 2002; 62(10): 2861 - 2868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Basak, A. Harui, M. Stolina, S. Sharma, K. Mitani, S. M. Dubinett, and M. D. Roth Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4 Blood, April 15, 2002; 99(8): 2869 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Rudolf, S. C. Fausch, D. M. Da Silva, and W. M. Kast Human Dendritic Cells Are Activated by Chimeric Human Papillomavirus Type-16 Virus-Like Particles and Induce Epitope-Specific Human T Cell Responses In Vitro J. Immunol., May 15, 2001; 166(10): 5917 - 5924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Billia, M. Barbara, J. McEwen, M. Trevisan, and N. N. Iscove Resolution of pluripotential intermediates in murine hematopoietic differentiation by global complementary DNA amplification from single cells: confirmation of assignments by expression profiling of cytokine receptor transcripts Blood, April 15, 2001; 97(8): 2257 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paczesny, S. Beranger, J.-L. Salzmann, D. Klatzmann, and B. M. Colombo Protection of Mice against Leukemia after Vaccination with Bone Marrow-derived Dendritic Cells Loaded with Apoptotic Leukemia Cells Cancer Res., March 1, 2001; 61(6): 2386 - 2389. [Abstract] [Full Text]
|
|
|
|
|
|
B. W. Tillman, T. L. Hayes, T. D. deGruijl, J. T. Douglas, and D. T. Curiel Adenoviral Vectors Targeted to CD40 Enhance the Efficacy of Dendritic Cell-based Vaccination against Human Papillomavirus 16-induced Tumor Cells in a Murine Model Cancer Res., October 1, 2000; 60(19): 5456 - 5463. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Ribas, L. H. Butterfield, and J. S. Economou Genetic Immunotherapy for Cancer Oncologist, April 1, 2000; 5(2): 87 - 98. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Gutiérrez-Rodríguez, E. Reyes-Maldonado, and H. Mayani Characterization of the Adherent Cells Developed in Dexter-Type Long-Term Cultures from Human Umbilical Cord Blood Stem Cells, January 1, 2000; 18(1): 46 - 52. [Abstract] [Full Text]
|
|
|
|
|
|
N. Yamada and S. I. Katz Generation of Mature Dendritic Cells from a CD14+ Cell Line (XS52) by IL-4, TNF-{alpha}, IL-1{beta}, and Agonistic Anti-CD40 Monoclonal Antibody J. Immunol., November 15, 1999; 163(10): 5331 - 5337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Langstein, J. Michel, and H. Schwarz CD137 Induces Proliferation and Endomitosis in Monocytes Blood, November 1, 1999; 94(9): 3161 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kaplan, Q. Yu, S. T. Piraino, S. E. Pennington, S. Shankara, L. A. Woodworth, and B. L. Roberts Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens J. Immunol., July 15, 1999; 163(2): 699 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mulders, C.-L. Tso, B. Gitlitz, R. Kaboo, A. Hinkel, S. Frand, S. Kiertscher, M. D. Roth, J. deKernion, R. Figlin, et al. Presentation of Renal Tumor Antigens by Human Dendritic Cells Activates Tumor-infiltrating Lymphocytes against Autologous Tumor: Implications for Live Kidney Cancer Vaccines Clin. Cancer Res., February 1, 1999; 5(2): 445 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Su, R. Messer, W. Whitmire, E. Fischer, J. C. Portis, and H. D. Caldwell Vaccination against Chlamydial Genital Tract Infection after Immunization with Dendritic Cells Pulsed Ex Vivo with Nonviable Chlamydiae J. Exp. Med., September 7, 1998; 188(5): 809 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Ahuja, S. Mummidi, H. L. Malech, and S. K. Ahuja Human Dendritic Cell (DC)-Based Anti-Infective Therapy: Engineering DCs to Secrete Functional IFN-{gamma} and IL-12 J. Immunol., July 15, 1998; 161(2): 868 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shortman and C. Caux Dendritic Cell Development: Multiple Pathways to Nature's Adjuvants Stem Cells, November 1, 1997; 15(6): 409 - 419. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
